InVivo aims to create a new care paradigm for SCI sufferers, transcending the current treatment options that only focus on the symptoms of SCI rather than the underlying pathology. Rather than focusing solely on regeneration, InVivo takes a unique approach to SCI. The company concentrates on neuroprotection, with products intended to protect the spinal cord by mitigating the bleeding, inflammation, and further cell death that result from the body’s immune response to SCI after primary injury. Curtailing these secondary injury processes and supporting subsequent repair and recovery can lead to neuroplasticity, or the body’s local reorganization toward functional recovery through the spared healthy tissue. This may result in partial functional recovery.
InVivo’s development portfolio is unmatched – composed of platform technologies for treating spinal cord injury and other applications. These technologies incorporate a number of strategies involving biomaterials, U.S. Food & Drug Administration (FDA) approved drugs, growth factors, and human neural stem cells.
InVivo’s affiliations include such illustrious entities as Massachusetts Institute of Technology, Harvard Medical School, Washington Brain and Spine Institute, Boston Bruins Foundation, and University of California, Los Angeles, among others.
InVivo’s technological research offers significant market opportunity and lucrative growth potential. It is estimated that 12,000 new cases of SCI occur each year in the United States, and approximately 1,275,000 people currently suffer paralysis due to SCI. The company’s products have substantial growth potential with considerable reward, as risk is allayed as a result of a shorter regulatory approval process for medical devices.
For further information about InVivo, visit www.invivotherapeutics.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
